Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,520.80
(
0.33%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
91.36
(
-0.89%
)
Bitcoin
73,306.44
(
-0.32%
)
News Focus
News Focus
Post# of 57990
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123038
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: atheroprevent post# 32646

Monday, 03/15/2010 3:46:26 PM

Monday, March 15, 2010 3:46:26 PM

Post# of 57990
Good point on the combination product called Valturna (#msg-41609619), which might suffer a modest setback from the failed Diovan study. However, the main reason for the slow uptake of Valturna has been that the medical community has not (yet) been sold on the benefits of the Tekturna component. Regards, Dew


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today